Wells Fargo & Company Issues Positive Forecast for Septerna (NASDAQ:SEPN) Stock Price

Septerna (NASDAQ:SEPN) had its price objective raised by Wells Fargo & Company from $28.00 to $48.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other equities analysts have also weighed in on SEPN. Raymond James Financial assumed coverage on shares of Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 target price for the company. Truist Financial initiated coverage on shares of Septerna in a report on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective for the company. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. JonesTrading initiated coverage on Septerna in a research report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 target price on the stock. Finally, Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Septerna Price Performance

Shares of SEPN opened at $28.13 on Tuesday. The firm has a market cap of $1.26 billion, a PE ratio of -18.63 and a beta of 3.46. Septerna has a 1 year low of $4.66 and a 1 year high of $32.63. The stock’s fifty day moving average price is $26.93 and its two-hundred day moving average price is $22.65.

Insider Buying and Selling at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SEPN. Woodline Partners LP raised its holdings in shares of Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after acquiring an additional 282,585 shares in the last quarter. Rhumbline Advisers increased its position in shares of Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares during the last quarter. Geode Capital Management LLC raised its stake in Septerna by 19.1% in the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Septerna in the second quarter valued at approximately $129,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Septerna by 116.7% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock valued at $2,354,000 after purchasing an additional 119,953 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.